BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 34675942)

  • 1. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
    Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
    Front Immunol; 2021; 12():765101. PubMed ID: 34675942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
    Caraballo Galva LD; Cai L; Shao Y; He Y
    J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives.
    Mandlik DS; Mandlik SK; Choudhary HB
    World J Gastroenterol; 2023 Feb; 29(6):1054-1075. PubMed ID: 36844141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects and Challenges for T Cell-Based Therapies of HCC.
    Woller N; Engelskircher SA; Wirth T; Wedemeyer H
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
    Repáraz D; Aparicio B; Llopiz D; Hervás-Stubbs S; Sarobe P
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.
    Wang K; Wang C; Jiang H; Zhang Y; Lin W; Mo J; Jin C
    Front Immunol; 2021; 12():792781. PubMed ID: 34975896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
    Büttner N; Schmidt N; Thimme R
    Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges.
    Wang L; Wang FS
    Hepatol Int; 2019 Sep; 13(5):521-533. PubMed ID: 31352593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological landscape and immunotherapy of hepatocellular carcinoma.
    Prieto J; Melero I; Sangro B
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic approaches for hepatocellular carcinoma.
    Longo V; Gnoni A; Casadei Gardini A; Pisconti S; Licchetta A; Scartozzi M; Memeo R; Palmieri VO; Aprile G; Santini D; Nardulli P; Silvestris N; Brunetti O
    Oncotarget; 2017 May; 8(20):33897-33910. PubMed ID: 28420805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
    Jiang Y; Han QJ; Zhang J
    World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma.
    Nakatsu G
    J Gastroenterol Hepatol; 2022 Jan; 37(1):34-38. PubMed ID: 34665475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
    Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.